Barry Selick, PhD

Vice Chancellor, Business Development, Innovation and Partnerships
Innovation Ventures
+1 650 483-1900

Prior to joining UCSF, Barry was the CEO of Threshold Pharmaceuticals, a fully integrated oncology drug discovery/clinical development company that he led as CEO from its Series A financing through IPO to its eventual sale in 2017. He was also a Venture Partner at Sofinnova Ventures from June 2002 until July 2007. Prior to Threshold, Barry co-founded and was CEO and Chairman of Camitro, a venture capital backed drug discovery technology company with teams in California and Cambridge, UK, which was acquired 2 years after its founding. Before Camitro, Barry was at Affymax Research Institute, which was acquired by Glaxo Wellcome, plc as its drug discovery technology development center and where Barry was Vice President of Research, responsible for technology development and drug discovery. Prior to Affymax, Barry was at Protein Design Labs (PDL) and Anergen. As a bench scientist at PDL, he co-invented the technology underlying fully humanized antibody therapeutics and applied that to daclizumab (Zenapax), the first FDA-approved fully humanized antibody therapeutic, that was licensed to and commercialized by Roche for the prevention of kidney transplant rejection. This technology has contributed to more than 15 FDA approved therapeutics with cumulative revenues in excess of $200B. Throughout his career, Barry has been a member of the Boards of Directors of a dozen both early stage venture capital-backed as well as public biotech companies and Chairman and/or Lead Director of 9 of those.

With a BA in Biophysics and PhD in Biology from the University of Pennsylvania, Barry was a Damon Runyan-Walter Winchell Cancer Fund Fellow as well as a Senior Fellow of the American Cancer Society at UCSF.